Department of Immunology and Rheumatology, Unit of Translational Medicine, Nagasaki University Graduate School of Biomedical Sciences, 1-7-1 Sakamoto, Nagasaki 852-8501, Japan.
Mod Rheumatol. 2013 May;23(3):582-6. doi: 10.1007/s10165-012-0680-3. Epub 2012 Jul 7.
We introduced abatacept (ABT) in a very early rheumatoid arthritis (RA) patient with active tenosynovitis of hands defined by musculoskeletal ultrasonography (MSKUS). MSKUS-proven tenosynovitis remarkably improved at 2 months in spite of clinical exacerbation, followed by clinical remission at 5 months. MSKUS abnormalities also disappeared. Although ABT was discontinued due to an adverse event after the sixth infusion, she remained in clinical remission as well as imaging remission by MSKUS at 13 months.
我们为一位非常早期的类风湿关节炎（RA）患者引入了阿巴西普（ABT），该患者手部的肌腱滑膜炎活动，通过肌肉骨骼超声（MSKUS）证实。尽管临床病情恶化，但在 2 个月时 MSKUS 证实的肌腱滑膜炎显著改善，随后在 5 个月时达到临床缓解。MSKUS 异常也消失了。尽管在第六次输注后因不良事件停用 ABT，但在 13 个月时，她仍然处于临床缓解和 MSKUS 影像学缓解状态。
